Replies to post #1803 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

I harken back to Viekira. What if ENTA had thrown in the towel after "failing" with that?

HCV might not be a helpful template for the way the NASH market will play out. NASH is a multifactorial and poorly understood disease, while HCV is neither.

p.s. Viekira had peak annual sales of $1.5B (in 2015), so it was by no means a complete bust.